Delaware
|
0-23047
|
13-3864870
|
(State or other jurisdiction of incorporation or organization)
|
(Commission file number)
|
(I.R.S. employer identification no.)
|
31 East 62nd Street
New York, New York
(Address of principal executive offices)
|
|
10065
(Zip code)
|
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
Trading
Symbol(s)
|
Name of each exchange on which registered
|
common stock, $.0001 par value
|
SIGA
|
The Nasdaq Global Market
|
Exhibit
No. |
|
Description
|
Amendment of Solicitation/Modification of Contract 0002, dated May 17, 2019, to Agreement, dated September 10, 2018, between the Biomedical Advanced
Research and Development Authority of the United States Department of Health and Human Services and SIGA Technologies, Inc. (Certain portions of this exhibit have been omitted pursuant to Rule 601(b)(10) of Regulation S-K. The omitted
information is (i) not material and (ii) would likely cause competitive harm to the Company if publicly disclosed).
|
||
Press Release, dated May 20, 2019.
|
|
SIGA TECHNOLOGIES, INC.
|
|
|
|
|
|
|
|
By:
|
/s/ Daniel J. Luckshire | |
|
Name:
|
Daniel J. Luckshire
|
|
|
Title:
|
Chief Financial Officer
|
|
|
|
|
|
Date: May 20, 2019
|
|
|
|
12. ACCOUNTING AND APPROPRIATION DATA (
if
required
) 2019.1990051.25106
|
Net Increase:
|
$11,255,170.00
|
13. THIS ITEM ONLY APPLIES TO MODIFICATION OF CONTRACTS/ORDERS. IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM
14.
|
|
CHECK
ONE
|
A. THIS CHANGE ORDER IS ISSUED PURSUANT TO: (
Specify authority
) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM 10A.
|
B. THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (
such as changes in paying office, appropriation date, etc.
) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(b).
|
|
X
|
C. THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF:
FAR 43.103(a) Bilateral Modification; FAR7.207(c)(1) Exercise of Options with Available Funds
|
D. OTHER (
Specify type of
modification and authority
)
|
E. IMPORTAN
T: Contractor ☐
is not. ☒ is required to sign this document and return
1
copies to
the issuing office.
|
|||
14. DESCRIPTION OF AMENDMENT/MODIFICATION (
Organized
by UCF section headings, including solicitation/contract subject matter where feasible.
)
|
|||
Tax ID Number: 13-3864870
|
|||
DUNS Number: 932651516
|
|||
Procurement and Late-Stage Development of Smallpox Antiviral Drug(s)
|
|||
The purpose of this modification is to (1) exercise Option CLIN0009a in the amount of $11,255,170.00, (2) modify Article G.2. to change
the Contracting Officer’s Representative as follows; (3) revise Article B.3. to breakout CLIN0009 into four subparts (0009a, 0009b, 0009c, 0009d) as follows.
|
|||
All other terms and conditions in the contract remain unchanged.
Delivery: [***]
Continued …
|
|||
Except as provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as heretofore
changed, remains unchanged and in full force and effect.
|
15A. NAME AND TITLE OF SIGNER (
Type or print
)
Dennis E. Hruby, CSO
|
16A. NAME AND TITLE OF CONTRACTING OFFICER (
Type
or print
)
Christopher Scott
|
||
15B. CONTRACTOR/OFFEROR
|
15C. DATE SIGNED
|
16B. UNITED STATES OF AMERICA
|
16C. DATE SIGNED
|
/s/ Dennis E. Hruby
|
16 May 2019
|
/s/ Christopher Scott
|
05/17/19
|
(
Signature of person authorized to sign
)
|
(
Signature of Controlling Officer
)
|
NSN 7540-01-152-8070
|
STANDARD FORM 30 (REV. 10-83)
|
Previous edition unusable
|
Prescribed by GSA
|
FAR (48 CFR) 53.243
|
CONTINUATION SHEET
|
REFERENCE NO. OF DOCUMENT BEING CONTINUED
HHSO100201800019C/P00002
|
PAGE OF
|
|
2
|
2
|
NAME OF OFFEROR OR CONTRACTOR
SIGA TECHNOLOGIES, INC. 1385150
|
|||||
ITEM NO
(A)
|
SUPPLIES/SERVICES
(B)
|
QUANTITY
(C)
|
UNIT
(D)
|
UNIT PRICE
(E)
|
AMOUNT
(F)
|
Delivery Location Code:
HHS/OS/ASPR
HHS/OS/ASPR
200 C St. SW
WASHINGTON DC 20201 US
|
|||||
Appr. Yr.: 2019 CAN: 1990051 Object Class: 25106
Period of Performance: 09/10/2018 to 09/09/2028
|
|||||
Add Item 3 as follows:
|
|||||
3
|
ASPR-19-01762 – Exercise of Option CLIN 0009a to
SIGA Technologies for Procurement of raw
materials used in the manufacturing of
unmicronized API in sufficient quantity to support the production of 363,070 courses
of nonparenteral (oral) formulated antiviral for SNS replenishment. Such raw
materials may be forward processed, under contract HHSO100201800019C
Obligated Amount: $11,255,170.00
|
11,255,170.00
|
|||
|
|||||
NSN 7540-01-152-8067 |
OPTIONAL FORM 336 (4-86)
Sponsored by GSA
FAR (48 CFR) 53.110
|
Modified
CLIN
|
Period of
Performance
|
Supplies/Services
|
Treatment
Courses (#
of Product)
|
Unit Price
($)
|
Total ($)
|
||||||
0009A
(Option -
EXERCISED)
|
[***]
|
Procurement of raw materials used in the manufacturing of unmicronized API in sufficient quantity to support the production of 363,070 courses of
nonparenteral (oral) formulated antiviral for SNS replenishment. Such raw materials may be forward processed.
|
363,070
(raw materials)
|
$31
|
$11,255,170
|
||||||
0009B
(Option)
|
[***]
|
Additional procurement of
nonparenteral (oral)
formulated
antiviral as FDP and delivery to the SNS
|
121,023
(finished product)
|
$279
|
$33,765,417
|
||||||
0009C
(Option)
|
[***]
|
Additional procurement of
nonparenteral (oral)
formulated
antiviral as FDP and delivery to the SNS
|
121,023
(finished product)
|
$279
|
$33,765,417
|
||||||
0009D
(Option)
|
[***]
|
Additional procurement of
nonparenteral (oral)
formulated
antiviral as FDP and delivery to the SNS
|
121,024
(finished product)
|
$279
|
$33,765,696
|
1
|
http://www.mayoclinic.org/diseases-conditions/smallpox/basics/definition/con-20022769
|